8-K current report · filed Nov 3, 2026

STANDARD BIOTOOLS INC. (LAB) 8-K Current Report: November 3, 2026

Item 7.01Item EX-99.1LAB overview

Short answer

STANDARD BIOTOOLS INC. (LAB) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Microfluidics business sale to ARCHIMED closed on November 3, 2026.

STANDARD BIOTOOLS INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Microfluidics business sale to ARCHIMED closed on November 3, 2026
  • Transaction completes Standard BioTools’ previously announced divestiture and transfers future business ownership to ARCHIMED
  • ARCHIMED assumes responsibility for integrating, developing, and commercializing Microfluidics technology and products
  • Sale announcement may signal portfolio streamlining as Standard BioTools pursues pending Treeline and Element transactions

Item EX-99.1 · Exhibit EX-99.1

  • ARCHIMED completed the acquisition of Standard BioTools’ Microfluidics Business, separating it from LAB’s operating portfolio
  • Business relaunched as Biomark Scientific, retaining the Biomark platform, Biomark X9 system and existing team
  • Biomark Scientific now operates as an independent ARCHIMED-backed company focused on genomic workflows, clinical research and public health
  • For LAB shareholders, transaction marks a portfolio shift toward Standard BioTools’ remaining life-science tools businesses and away from microfluidics നേതൃത്വം

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other STANDARD BIOTOOLS INC. 8-K filings

Get the next LAB 8-K as it lands

Follow LAB for push alerts, or ask the research agent what this filing means.